Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Mol Cell Cardiol. 2015 Aug 4;87:152–159. doi: 10.1016/j.yjmcc.2015.07.031

Figure 3. Nifedipine treatment reduces enlargement of abdominal aorta and prevents vascular remodeling in Ang II-Infused hph-1 mice.

Figure 3

Figure 3

A) Ultrasound determination of AAA development in Nifedipine treated, Ang II infused hph-1 mice. Representative images of ultrasound taken from Ang II infused (0.7 mg/kg per day, 2 weeks) hph-1 animals without (top row), and with low dose (5 mg/kg/day, middle row) or high dose (20 mg/kg/day, bottom row) of Nifedipine treatment. B) Summarized data from ultrasound measurements of abdominal aorta sizes. Nifedipine significantly prevented expansion of abdominal aorta at 2 weeks. **p<0.05, n=5–10. C) Nifedipine prevents vascular remodeling in Ang II infused hph-1 mice. Ang II infused hph-1 mice were treated with Nifedipine (5 or 20 mg/kg/day) 2 days before Ang II infusion and throughout the study period of 14 days, after which aortas were harvested for hematoxylin-eosin (H&E) staining. Left arrow on the left panel shows the flattening of the elastin fibers, while the right arrow on the left panel show the enlargement of the adventitial layer, both of these features were completely attenuated in the Nifedipine treated animals as in the middle (low dose) and right panels (high dose).